Tanaka, Yoshiya http://orcid.org/0000-0002-0807-7139
Barrett, Claire http://orcid.org/0000-0002-0362-0382
Hirano, Yuji http://orcid.org/0000-0002-0422-8139
Ikeda, Kei http://orcid.org/0000-0003-0574-9611
Paizis, Kathy http://orcid.org/0000-0002-3580-1970
Sameshima, Azusa http://orcid.org/0000-0002-8087-6066
Mountian, Irina http://orcid.org/0000-0002-1510-6428
Wong, Priscilla C. http://orcid.org/0000-0001-8713-9539
Funding for this research was provided by:
UCB Pharma
Article History
Received: 5 July 2022
Accepted: 1 September 2022
First Online: 26 September 2022
Declarations
:
: Y. Tanaka: Speakers’ fees and/or honoraria from AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, GSK, Mitsubishi-Tanabe and Pfizer; Research grants from AbbVie, Asahi-Kasei, Boehringer Ingelheim, Chugai, Daiichi-Sankyo, Eisai and Takeda. C. Barrett: President of Australian Rheumatology Association (since May 2022). Y. Hirano: None. K. Ikeda: Speakers’ fees and/or honoraria from AbbVie, Asahi-Kasei, Eisai, Eli Lilly, Gilead, Mitsubishi-Tanabe, Novartis, Pfizer, UCB; Research grants from Mitsubishi-Tanabe. K. Paizis: Speakers’ fees and/or honoraria from Praxhub. A. Sameshima: Speakers’ fees and/or honoraria from Astellas, Mitsubishi-Tanabe and UCB. I. Mountian: Employee and shareholder of UCB Pharma. P. Wong: None.
: Since this was a market research study, prior approval of the protocol by an ethics committee was not required. As both market research companies involved are based in Australia, the study was conducted in accordance with Australian market research guidelines, including the obtaining of informed consent and adherence to ethical reporting standards.